Table 3.

Accrued duration of BVAS = 0 and proportion of patients achieving BVAS = 0 during the treatment period

	PBO	Mepo
	(n = 68)	(n = 68)
Accrued duration of BVAS = 0 over 52 wk, n (%)
0	6 (9)	3 (4)
>0 to <12 wk	15 (22)	13 (19)
12 to <24 wk	11 (16)	5 (7)
24 to <36 wk	17 (25)	2 (3)
≥36 wk	19 (28)	45 (66)
OR (95% CI) a	3.71 (1.82, 7.60);
P value	P < 0.001
Proportion of patients with BVAS = 0 at Weeks 36 and 48, n (%)	23 (34)	34 (50)
OR (95% CI) a	1.94 (0.90, 4.19);
P value	P = 0.092

Abbreviations: BVAS, Birmingham Vasculitis Activity Score; CI, confidence interval; Mepo, mepolizumab; OR, odds ratio; PBO, placebo.

^a Mepolizumab versus placebo.